<DOC>
	<DOCNO>NCT02350218</DOCNO>
	<brief_summary>The purpose study evaluate superiority Eglandin® ( Alprostadil ) 720㎍compared 360㎍ term safety , efficacy live donor liver transplant patient , peak AST level follow Eglandin administration assess .</brief_summary>
	<brief_title>Safety Efficacy Study Eglandin Living Donor Liver Transplant Patient</brief_title>
	<detailed_description />
	<mesh_term>Alprostadil</mesh_term>
	<criteria>1 . Primary living donor liver transplantation 2 . Patient receive modified right lobe graft 3 . Aged 19 65 year 4 . Informed consent 1 . ABO incompatibility 2 . Dual liver transplant patient 2 donor 3 . History liver transplantation organ transplantation 4 . Transplantation organ ( ) time liver transplantation 5 . Use artificial liver device prior liver transplantation 6 . UNOS status Ⅰor ⅡA 7 . History malignant tumor within 5 year 8 . Not included Milan liver transplant criterion hepatocellular carcinoma 9 . Patient WBC &lt; 2,000/mm3 ANC &lt; 900/mm3 platelet &lt; 30,000/mm3 time screen 10 . Patient expose severe systemic infection require treatment 11 . Positive response HIV either donor recipient 12 . Prior administration investigational product within 30 day ( 5 time half life ) date screen 13 . Women childbearing age without effective contraception , breast feeding pregnant woman 14 . Substance abuser , patient metal disorder , otherwise legally eligible patient 15 . Not eligible participate discrete study investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Transplantation</keyword>
	<keyword>Living donor</keyword>
	<keyword>Eglandin</keyword>
	<keyword>Alprostadil</keyword>
</DOC>